Skip to main content
Journal cover image

Factors Associated With Systemic Immune Activation Indices in a Global Primary Cardiovascular Disease Prevention Cohort of People With Human Immunodeficiency Virus on Antiretroviral Therapy.

Publication ,  Journal Article
Looby, SE; Kantor, A; Burdo, TH; Currier, JS; Fichtenbaum, CJ; Overton, ET; Aberg, JA; Malvestutto, CD; Bloomfield, GS; Erlandson, KM; Masiá, M ...
Published in: Clin Infect Dis
October 12, 2022

BACKGROUND: Among antiretroviral therapy (ART)-treated people with human immunodeficiency virus (PWH), persistent systemic immune activation contributes to atherogenesis atherosclerotic, cardiovascular disease (CVD) events, and mortality. Factors associated with key immune activation indices have not previously been characterized among a global primary CVD prevention cohort of PWH. METHODS: Leveraging baseline Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) data, we evaluated factors associated with soluble CD14 (sCD14) and oxidized low-density lipoprotein (oxLDL). RESULTS: The primary analysis cohort included 4907 participants from 5 global-burden-of-disease regions (38% female, 48% Black, median age 50 years). In fully adjusted models for sCD14, female sex and White race (among those in high-income regions) were associated with higher sCD14 levels, while higher body mass index (BMI) and current use of nucleoside reverse transcriptase inhibitor + integrase strand transfer inhibitor ART were associated with lower sCD14 levels. In fully adjusted models for oxLDL, male sex, residence in high-income regions, White race (among those in high-income regions), and higher BMI were associated with higher oxLDL levels. In a subanalysis cohort of 1396 women with HIV, increased reproductive age was associated with higher sCD14 levels but not with higher oxLDL levels. CONCLUSIONS: Factors associated with sCD14 and oxLDL, 2 key indices of immune-mediated CVD risk, differ. Future studies will elucidate ways in which medications (eg, statins) and behavioral modifications influence sCD14 and oxLDL and the extent to which dampening of these markers mediates CVD-protective effects. CLINICAL TRIALS REGISTRATION: NCT0234429.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Clin Infect Dis

DOI

EISSN

1537-6591

Publication Date

October 12, 2022

Volume

75

Issue

8

Start / End Page

1324 / 1333

Location

United States

Related Subject Headings

  • Reverse Transcriptase Inhibitors
  • Nucleosides
  • Middle Aged
  • Microbiology
  • Male
  • Lipoproteins, LDL
  • Lipopolysaccharide Receptors
  • Integrases
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Humans
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Looby, S. E., Kantor, A., Burdo, T. H., Currier, J. S., Fichtenbaum, C. J., Overton, E. T., … Zanni, M. V. (2022). Factors Associated With Systemic Immune Activation Indices in a Global Primary Cardiovascular Disease Prevention Cohort of People With Human Immunodeficiency Virus on Antiretroviral Therapy. Clin Infect Dis, 75(8), 1324–1333. https://doi.org/10.1093/cid/ciac166
Looby, Sara E., Amy Kantor, Tricia H. Burdo, Judith S. Currier, Carl J. Fichtenbaum, Edgar T. Overton, Judith A. Aberg, et al. “Factors Associated With Systemic Immune Activation Indices in a Global Primary Cardiovascular Disease Prevention Cohort of People With Human Immunodeficiency Virus on Antiretroviral Therapy.Clin Infect Dis 75, no. 8 (October 12, 2022): 1324–33. https://doi.org/10.1093/cid/ciac166.
Looby SE, Kantor A, Burdo TH, Currier JS, Fichtenbaum CJ, Overton ET, Aberg JA, Malvestutto CD, Bloomfield GS, Erlandson KM, Cespedes M, Kallas EG, Masiá M, Thornton AC, Smith MD, Flynn JM, Kileel EM, Fulda E, Fitch KV, Lu MT, Douglas PS, Grinspoon SK, Ribaudo HJ, Zanni MV. Factors Associated With Systemic Immune Activation Indices in a Global Primary Cardiovascular Disease Prevention Cohort of People With Human Immunodeficiency Virus on Antiretroviral Therapy. Clin Infect Dis. 2022 Oct 12;75(8):1324–1333.
Journal cover image

Published In

Clin Infect Dis

DOI

EISSN

1537-6591

Publication Date

October 12, 2022

Volume

75

Issue

8

Start / End Page

1324 / 1333

Location

United States

Related Subject Headings

  • Reverse Transcriptase Inhibitors
  • Nucleosides
  • Middle Aged
  • Microbiology
  • Male
  • Lipoproteins, LDL
  • Lipopolysaccharide Receptors
  • Integrases
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Humans